Moreover, DUSP1 targeting leads to increased levels of p-ERK1 and p-ERK2 [15], and ERK activation in pancreatic cancer cells enhances gemcitabine chemoresistance [28]. The gene discussed is MAPK1; the disease is familial pancreatic carcinoma.